May 14 (Reuters) - EyePoint said on Thursday an independent safety committee found no new concerns in two late-stage trials of its experimental eye disease drug Duravyu and recommended the studies ...

A new federally funded research effort in Rochester is aiming to tackle one of the biggest gaps in treating age-related macular degeneration — stopping vision loss before it starts. Researchers at ...

Significantly lower AMD risk compared with other agents in cohort study ...

(WISH) — There are two types of macular degeneration: dry and wet. Dry, age-related macular degeneration is the most common type; it happens when small deposits form under the retina, causing cells in ...

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...

Outlook Therapeutics received notice that the Food and Drug Administration can't approve its biologics license application for a drug designed to treat macular degeneration. The Iselin, N.J., ...

Following a year of uncertainty surrounding federal biomedical research funding, BrightFocus Foundation provides critical support for innovative brain and eye research BrightFocus Foundation today ...

There is strong interest across many stakeholders to increase progress around developing treatments for dry age-related macular degeneration (AMD). Advancements in drug discovery and development in ...

Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD). A new study, ...